Cargando…

Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease

INTRODUCTION: Thrombocytopenia can increase the bleeding risk in patients with chronic liver disease (CLD) undergoing invasive procedures. Prophylactic platelet transfusion (PT) is often performed to increase platelet counts in patients with CLD undergoing invasive procedures to prevent bleeding. Lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Manami, Tateishi, Ryosuke, Hiroi, Shinzo, Hongo, Yoshie, Fujiwara, Masakazu, Kitanishi, Yoshitake, Iwasaki, Kosuke, Takeshima, Tomomi, Igarashi, Ataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799534/ https://www.ncbi.nlm.nih.gov/pubmed/34748184 http://dx.doi.org/10.1007/s12325-021-01965-7

Ejemplares similares

Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data
por: Yoshida, Manami, et al.
Publicado: (2021)

Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
por: Kondoh, Yasuhiro, et al.
Publicado: (2022)

Bleeding events in lusutrombopag‐treated thrombocytopenic patients
por: Giannini, Edoardo Giovanni, et al.
Publicado: (2021)

Diagnosis and treatment of influenza based on health insurance claims between the 2010–2011 and 2019–2020 influenza seasons in Japan
por: Shimizu, Eiko, et al.
Publicado: (2022)

Comparison of Inconvenience Costs Between Influenza Antivirals for Japanese Pediatric Patients: A Conjoint Analysis of Parental Responses
por: Kurazono, Kenji, et al.
Publicado: (2022)

Analysis of antihypertensive treatment using real-world Japanese data—the retrospective study of antihypertensives for lowering blood pressure (REAL) study
por: Ohishi, Mitsuru, et al.
Publicado: (2019)

A cost‐effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan
por: Miki, Norikane, et al.
Publicado: (2021)

Opioid prescriptions at the point of surgery, bone metastasis, or death among patients with breast cancer in Japanese acute care hospitals: a claims-based, retrospective, longitudinal study
por: Yoshida, Manami, et al.
Publicado: (2023)

Estimation of Intangible Costs for Factors Associated with Oral Antiviral Drugs for COVID-19 Treatment: A Conjoint Analysis in Japan
por: Hosogaya, Naoki, et al.
Publicado: (2023)

Patient journey through cases of depression from claims database using machine learning algorithms
por: Kitanishi, Yoshitake, et al.
Publicado: (2021)

Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance
por: Sasaki, Ritsue, et al.
Publicado: (2019)

Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database
por: Ogino, Mieko, et al.
Publicado: (2017)

Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database
por: Kawachi, Izumi, et al.
Publicado: (2019)

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

Relationship between response to lusutrombopag and splenic volume
por: Uojima, Haruki, et al.
Publicado: (2018)

In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data
por: Izumi, Chisato, et al.
Publicado: (2023)

Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
por: Ding, Zhenbin, et al.
Publicado: (2022)

Bleeding assessment and bleeding severity in thrombocytopenic patients undergoing invasive procedures
por: van Baarle, Frank E.H.P., et al.
Publicado: (2020)

A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study
por: Yoshida, Hideo, et al.
Publicado: (2023)

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures
por: Nishida, Yuno, et al.
Publicado: (2020)

Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
por: Sakamaki, Akira, et al.
Publicado: (2017)

Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag
por: Brown, Robert S., et al.
Publicado: (2021)

Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data
por: Hiroi, Shinzo, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Katsube, Takayuki, et al.
Publicado: (2019)

Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures
por: Takada, Hitomi, et al.
Publicado: (2019)

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)
por: Peck‐Radosavljevic, Markus, et al.
Publicado: (2019)

A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series
por: Biolato, Marco, et al.
Publicado: (2022)

Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia
por: Ishikawa, Toru, et al.
Publicado: (2019)

Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database
por: Ogino, Mieko, et al.
Publicado: (2016)

Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS
por: Wang, Bo, et al.
Publicado: (2020)

Determination of optimal prevention strategy for COVID-19 based on multi-agent simulation
por: Fujita, Satoki, et al.
Publicado: (2022)

Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Orme, Michelle E., et al.
Publicado: (2022)

Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates
por: Fustolo-Gunnink, Susanna F., et al.
Publicado: (2019)

Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment
por: Sato, Shuichi, et al.
Publicado: (2017)

Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters
por: Katsube, Takayuki, et al.
Publicado: (2020)

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study
por: Nomoto, Hiroaki, et al.
Publicado: (2020)

Not all thrombocytopenic bleeding is the same: Response to Singh et al.
por: Singh, Suvir
Publicado: (2021)

Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism
por: Wilson, Nathaniel R., et al.
Publicado: (2020)

Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study
por: Odawara, Masato, et al.
Publicado: (2021)

Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis
por: Nishimura, Rimei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ertn64rbocgk4sm592udhl0jl7